Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy.

@article{Nagar2010PharmacokineticsOA,
  title={Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy.},
  author={S. Nagar},
  journal={Advances in experimental medicine and biology},
  year={2010},
  volume={678},
  pages={
          124-32
        }
}
  • S. Nagar
  • Published 2010
  • Medicine
  • Advances in experimental medicine and biology
Pharmacokinetics of anticancer drugs used in breast cancer therapy are well established. This chapter reviews preclinical and clinical pharmacokinetics of the following drugs: cyclophosphamide, docetaxel, doxorubicin, 5-fluorouracil, methotrexate and tamoxifen. The absorption, distribution, metabolism and elimination of drugs are discussed in the context of breast cancer. The effect of age and menopause status on drug pharmacokinetics is evaluated. The important role of pharmacokinetic… Expand
Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs
TLDR
This review summarizes the pharmacokinetics of various types of drugs used to treat breast cancer and discusses hormone-related variations including: the menstrual status, gender and exogenous hormones influencing drug absorption, distribution, metabolism or excretion. Expand
Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models.
TLDR
The protocols of PK and PD studies in breast cancer models to assess the efficacy of an anti-breast cancer compound are described, noting the types and endpoints employed, and why it is important to link PK andPD in order to establish and evaluate dose/concentration-response relationships and subsequently describe and predict the effect-time courses for a given drug dose are described. Expand
Pharmacokinetics and Pharmacogenetics of Metronomic Chemotherapy
TLDR
Trials integrating pharmacokinetic and pharmacogenetics research are necessary to better evaluate the clinical benefit of metronomic chemotherapy. Expand
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors
TLDR
The effectiveness of a combination of real-time reporters of TRAIL-induced apoptosis pathway in evaluating the efficacy of SC-TRAIL-based therapeutics is demonstrated and may have implications in targeting a broad range of cancers. Expand
Nano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics
TLDR
This review addresses the rise of nanoparticle DDS platforms for cancer and explores concepts of gene/drug delivery and cytotoxicity in pre-clinical and clinical contexts. Expand
Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells.
TLDR
The results suggest that a low concentration of luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 cells through a combination of antioxidant activity and an increase in levels of Bcl-2 protein. Expand
Therapy-induced senescence drives bone loss.
TLDR
The understanding of chemotherapy-induced bone loss is transformed by identifying senescent cells as major drivers of bone loss and the p38MAPK-MK2 axis as a putative therapeutic target that can preserve bone and improve a cancer survivor's quality of life. Expand
Chemotherapy-Induced Late Transgenerational Effects in Mice
To our knowledge, there is no report on long-term reproductive and developmental side effects in the offspring of mothers treated with a widely used chemotherapeutic drug such as doxorubicin (DXR),Expand
Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance
TLDR
Investigation of the role of organic anion transporting polypeptide (OATP) transporters to the disposition of doxorubicin demonstrates important roles for OATP1A/1B in transporter-mediated uptake and disposition ofDoxorUBicin. Expand
Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study
TLDR
It is suggested that the cancer-related exposome has an impact on both healthy somatic cells and tumor cells, and may lead to persistent chromosome instability, and interventions that aim to reduce stress may reduce acquired soma-wide chromosomal instability for cancer survivors. Expand
...
1
2
...

References

SHOWING 1-10 OF 55 REFERENCES
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
TLDR
Docetaxel monotherapy has shown impressive activity as second-line therapy in patients with metastatic breast cancer who had relapsed while receiving adjuvant therapy or who had progressive disease following previous treatment, with overall response rates of 53 and 58% reported in 2 studies. Expand
Clinical Pharmacokinetics of Docetaxel
TLDR
Strategies to individualise docetaxel administration schedules based on phenotypic or genotype-dependent differences in CYP3A expression are underway and may ultimately lead to more selective chemotherapeutic use of this agent. Expand
Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
TLDR
To increase knowledge aiming at optimisation of cancer treatment in elderly, there is a clear necessity for prospective, well-designed studies with emphasis on the particular requirements of older patients and incorporation of pharmacokinetic and -dynamic evaluation of cytotoxic agents used in this specific group. Expand
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.
TLDR
It appears that a substantial part of 5-FU toxicity is not linked to pharmacokinetic factors and dose adjustments must still be on the basis of careful clinical surveillance. Expand
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
  • J. Schellens, M. Malingré, +4 authors J. Beijnen
  • Medicine
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2000
TLDR
The background and recent results of modulation of oral bioavailability of poorly available drugs, focused on drug transport systems and CYP in gut wall and liver are described and summarized. Expand
Preclinical pharmacokinetics of paclitaxel and docetaxel.
TLDR
Paclitaxel and docetaxel widely distribute into most tissues of mice and rats, including tumor tissue, but only low concentrations were detected in the central nervous system, and their metabolic profile is very distinct. Expand
Pharmacology of cancer chemotherapy in the older person.
TLDR
The relevant age-related factors that may alter drug disposition and its relationship to pharmacokinetics effects and to pharmacodynamic effects in the elderly are reviewed. Expand
Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer
TLDR
There is no pharmacokinetic interaction between tamoxifen and exemestane and no modification in the standard regimen of either drug seems to be indicated if they are used in combination. Expand
Clinical Pharmacokinetics of Cyclophosphamide
TLDR
Variations in the balance between metabolic activation and inactivation of cyclophosphamide owing to autoinduction, dose escalation, drug-drug interactions and individual differences have been reported, suggesting possibilities for optimisation of cyclphosphamide therapy. Expand
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
  • J. Ingle, V. Suman, +7 authors M. Dowsett
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
TLDR
Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM, and the antitumor effect of TAM plus letroZole was less than expected. Expand
...
1
2
3
4
5
...